Coccidioides Antibodies, IgM and IgG by Immunoassay, CSF
Also known as: COCCIGMCSF
Use
The test is used to screen for the presence of coccidioidal IgM and IgG antibodies in CSF. It is not recommended as a standalone test. The presence of IgG antibodies suggests current or past infection, as IgG antibodies usually appear by the third week of infection and may persist for years. IgM antibodies indicate current or recent infection, usually appearing by the second week and disappearing by the fourth month. The test uses recombinant and native Coccidioides antigens, including CF and TP antigens.
Special Instructions
For comprehensive diagnostic testing that includes immunoassay (IgM and IgG), complement fixation, and immunodiffusion, refer to Coccidioides Antibodies Panel, CSF (3000061). Parallel testing is preferred, and convalescent specimens must be received within 30 days from receipt of the acute specimens. Mark specimens plainly as 'acute' or 'convalescent'.
Limitations
Positive EIA results should be confirmed with immunodiffusion (ID) or complement fixation (CF) tests. If ID or CF tests do not corroborate the EIA results, the diagnosis is less firmly established. The test is not recommended as a standalone diagnostic test for coccidioidomycosis. It should be used in conjunction with other clinical findings and tests.
New York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 16638-9
- 16639-7
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
0.3 mL
Container
ARUP Standard Transport Tube
Causes for Rejection
Other body fluids. Contaminated, hemolyzed, xanthochromic, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year (avoid repeated freeze/thaw cycles) |